IMM

Immupharma PLC

Health Care First-pass screen £25m

260/1000 Overall fit

AI beneficiary 35% 25

Operating leverage 25% 30

Valuation 25% 30

Downside protection 15% 18

First-pass take

Pre-commercial biotech with zero revenue, negative equity (−£0.54m), and £2m annual cash burn. No AI exposure in strategy. P140 autoimmune platform shows scientific progress but requires sustained funding; completed dilutive £2.91m fundraise Feb 2025 at 3.75p/share.

Flags

loss-makingno-revenuegoing-concernnegative-equityhigh-burn-raterecent-dilutive-fundraiseno-valuation-data